Nick is an Econometrician and winner of the 2014 and 2015 Jim and Margaret Beever Fellowships. Since completing his mathematics PhD in 2012, he has built and used numerous mathematical, economic and statistical models to inform government policies, including:
Econometric and regression models of the heroin and methamphetamine markets in Melbourne, using data from cohort studies and the Victoria Police Forensic Services database—with submissions to the 2014 Victorian Parliamentary Inquiry into the Supply and Use of Methamphetamine and 2015 Ice Taskforce;
Markov models of the behavioural responses of people who inject drugs to changes in drug market economics;
Deterministic transmission models of hepatitis B virus, HIV and other sexually transmitted infections in prisons to determine the cost-benefits of condom availability;
Cost-effectiveness models of hepatitis C virus (HCV) treatment, including quantifying the impact of treating chronic HCV on the overall burden of liver disease, determining the cost-effectiveness of treating people who inject drugs with new therapies, determining the cost-effectiveness of reaching World Health Organisation elimination targets, and investigating the benefits of HCV vaccines;
A stochastic agent-based model ‘SimDrink’, currently being used to conduct alcohol policy experiments on populations of young heavy drinkers; and
Components of an allocative efficiency model as part of the ‘OptimaTB’ collaboration, designed to improve tuberculosis outcomes by optimising government funding allocation across preventative and treatment programs.
Listen to Dr Scott on Episode 7 of our How Science Matters podcast
- 2012: PhD in Mathematics, The University of Melbourne
- 2008: BSc (Hons), The University of Melbourne
Cost-effectiveness evidence for maternal and perinatal health interventions
Cost-effectiveness of antenatal corticosteroids for women at risk of imminent preterm birth in the early preterm period in low resource countries
COVASIM: Modelling COVID-19
Decision science using Optima
HCV Elimination Modelling
Hepatitis B Modelling
Hepatitis C brief reports
Modelling for evidence-based national hepatitis B testing plans
Modelling hepatitis C virus elimination and control policies in Myanmar
Optimal community-delivered malaria elimination models for the Greater Mekong Sub-region
SimDrink: Using simulation modelling to perform alcohol policy experiments
STRIVE PNG: Stronger Surveillance and Systems Support for Rapid Identification and Containment of Resurgent or Resistant Vector-Borne Pathogens in Papua New Guinea
The elimination of hepatitis C as a global public health threat
The International Collaboration on Hepatitis C Elimination in HIV Cohorts (InCHEHC)
The Optimise Study: Optimising Isolation, Quarantine and Distancing for COVID-19
The QuickStart Study
Tools for the Integrated Management of Childhood Illness (Kenya, Myanmar and Senegal)
- Melbourne COVID-19 roadmap modelling 2021 - 15 October 2021.(PUBLIC HEALTH REPORT)
Know-C19. 2021 Oct
- Cost effectiveness of simplified HCV screening-and-treatment interventions for people who inject drugs in Dar-es-Salaam, Tanzania.
Mohamed Z, Scott N, Nayagam S, Rwegasha J, Mbwambo J, Thursz MR, Brown AS, Hellard M, Lemoine M
Int J Drug Policy. 2021 Oct; 99:103458
- Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis.
Lim AG, Scott N, Walker JG, Hamid S, Hellard M, Vickerman P
PLoS Med. 2021 Oct; 18(10):e1003818
- Psychiatric well-being among men leaving prison reporting a history of injecting drug use: A longitudinal analysis.
Stewart AC, Cossar R, Wilkinson AL, Scott N, Dietze P, Quinn B, Kinner SA, Aitken C, Walker S, Curtis M, Butler T, Ogloff JRP, Stoové M
Aust N Z J Psychiatry. 2021 Sep; Epub ahead of print:48674211048143
- Modelling the Victorian roadmap (PUBLIC HEALTH REPORT)
Abeysuriya R, Delport D, Sacks-Davis R, Hellard M, Scott N
Know-C19. 2021 Sep; September:1-23
- A modelling analysis of financial incentives for hepatitis C testing and treatment uptake delivered through a community-based testing campaign.
Palmer AY, Chan K, Gold J, Layton C, Elsum I, Hellard M, Stoove M, Doyle JS, Pedrana A, Scott N; EC Partnership
J Viral Hepat. 2021 Aug; Epub ahead of print
- Evaluation of the effectiveness and cost effectiveness of a Community-delivered Integrated Malaria Elimination (CIME) model in Myanmar: protocol for an open stepped-wedge cluster-randomised controlled trial.
Oo WH, Thi A, Htike W, Agius PA, Cutts JC, Win KM, Yi Linn NY, Than WP, Hkawng GN, Thu KM, Oo MC, O'Flaherty K, Kearney E, Scott N, Phyu PP, Htet AT, Myint O, Lwin Yee L, Thant ZP, Mon A, Htike S, Hnin TP, Fowkes FJI
BMJ Open. 2021 Aug; 11(8):e050400
- Covasim: An agent-based model of COVID-19 dynamics and interventions.
Kerr CC, Stuart RM, Mistry D, Abeysuriya RG, Rosenfeld K, Hart GR, Núñez RC, Cohen JA, Selvaraj P, Hagedorn B, George L, Jastrzębski M, Izzo AS, Fowler G, Palmer A, Delport D, Scott N, Kelly SL, Bennette CS, Wagner BG, Chang ST, Oron AP, Wenger EA, Panovska-Griffiths J, Famulare M, Klein DJ
PLoS Comput Biol. 2021 Jul; 17(7):e1009149
- The introduction of a mandatory mask policy was associated with significantly reduced COVID-19 cases in a major metropolitan city.
Scott N, Saul A, Spelman T, Stoove M, Pedrana A, Saeri A, Grundy E, Smith L, Toole M, McIntyre CR, Crabb BS, Hellard M
PLoS One. 2021 Jul; 16(7):e0253510
- COVID-19 NSW outbreak (PUBLIC HEALTH REPORT)
Scott N, Hellard M, Abeysuriya R
Know-C19 Public Health Report. 2021 Jul
- COVASIM modelling: Impact of vaccines on epidemic outcomes. (PUBLIC HEALTH REPORT)
Abeysuriya R, Hellard M, Scott N
Know-C19. 2021 Jun; June:1-2
- Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits.
Scott N, Win TM, Tidhar T, Htay H, Draper B, Aung PTZ, Xiao Y, Bowring A, Kuschel C, Shilton S, Kyi KP, Naing W, Aung KS, Hellard M
Lancet Reg Health West Pac. 2021 May; 10:100129
- Role of masks, testing and contact tracing in preventing COVID-19 resurgences: a case study from New South Wales, Australia
Stuart RM, Abeysuriya RG, Kerr CC, Mistry D, Klein DJ, Gray RT, Hellard M, Scott N
BMJ Open. 2021 Apr; 11(4):e045941
- Prevalence and correlates of simultaneous, multiple substance injection (co-injection) amongst people who inject drugs in Melbourne, Australia.
Palmer A, Higgs P, Scott N, Agius P, Maher L, Dietze P
Addiction. 2021 Apr; 116(4):876-888
- A mobile phone application for malaria case-based reporting to advance malaria surveillance in Myanmar: a mixed methods evaluation.
Oo WH, Htike W, Cutts JC, Win KM, Thu KM, Oo MC, Hkawng GN, Agius PA, Htoon PP, Scott N, Kearney E, Moreira C, Pedrana A, Stoove M, Thi A, Aung YW, Thein MM, Rosecrans K, Lwin KT, Min AK, Fowkes FJI
Malar J. 2021 Mar; 20(1):167
- A costing analysis of a state-wide, nurse-led hepatitis C treatment model in prison.
Palmer A, Papaluca T, Stoové M, Winter R, Pedrana A, Hellard M, Wilson D, Thompson A, Scott N; EC Victoria Partnership.
Int J Drug Policy. 2021 Mar; 94:103203
- Estimating the number of new hepatitis C infections in Australia in 2015, prior to the scale-up of direct-acting antiviral treatment.
Palmer AY, Wilkinson A, Aitken C, Dietze P, Dore GJ, Maher L, Sacks-Davis R, Stoové M, Wilson D, Hellard M, Scott N
J Gastroenterol Hepatol. 2021 Mar; 36(8):2270-2274
- A global investment framework for the elimination of hepatitis B.
Howell J, Pedrana A, Schroeder SE, Scott N, Aufegger L, Atun R, Baptista-Leite R, Hirnschal G, Hoen E', Hutchinson SJ, Lazarus JV, Olufunmilayo L, Peck R, Sharma M, Sohn AH, Thompson A, Thursz M, Wilson D, Hellard M
J Hepatol. 2021 Mar; 74(3):535-549
- A Systematic Review of Interventions Used to Increase Blood Donor Compliance with Deferral Criteria.
Cutts JC, Quinn B, Seed CR, Kotsiou G, Pearson R, Scott N, Wilson DP, Harrod ME, Maher L, Caris S, Thompson AJ, Farrell M, Pink J, Hellard ME
Transfus Med Hemother. 2021 Mar; 48(2):118-129
- The cost-effectiveness of tranexamic acid for treatment of postpartum hemorrhage: A systematic review.
Aziz S, Rossiter S, Homer CSE, Wilson AN, Comrie-Thomson L, Scott N, Vogel JP
Int J Gynaecol Obstet. 2021 Feb; Epub ahead of print
- Modelling the impact of reducing control measures on the COVID-19 pandemic in a low transmission setting.
Scott N, Palmer A, Delport D, Abeysuriya R, Stuart R, Kerr CC, Ministry D, Klein D, Sacks-Davis R, Heath K, Hainsworth S, Pedrana A, Stoové M, Wilson D, Hellard ME
Med J Aust. 2021 Feb; 214(2):79-83
- Upscaling prevention, testing and treatment to control hepatitis C as a public health threat in Dar es Salaam, Tanzania: A cost-effectiveness model.
Scott N, Mohamed Z, Rwegasha J, Mbwambo J, Lemoine M, Hellard M
Int J Drug Policy. 2021 Jan; Epub ahead of print:102634
- Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
Tordrup D, Hutin Y, Stenberg K, Lauer JA, Hutton DW, Toy M, Scott N, Chhatwal J, Ball A
Value Health. 2020 Dec; 23(12):1552-1560
- Striving for hepatitis C elimination - the role of a vaccine.
Hellard M, Drummer H, Scott N
Clin Infect Dis. 2020 Dec; 77(11):2991-2992
- Ending malnutrition in all its forms requires scaling up proven nutrition interventions and much more: a 129-country analysis.
Scott N, Delport D, Hainsworth S, Pearson R, Morgan C, Huang S, Akuoku JK, Piwoz E, Shekar M, Levin C, Toole M, Homer CS
BMC Med. 2020 Nov; 18(1):356
- Impact of Victoria's Stage 3 lockdown on COVID-19 case numbers
Saul A, Scott N, Crabb BS, Majumdar SS, Coghlan B, Hellard ME
MJA. 2020 Nov; 213(11):494-496
- Gender inequalities in health and wellbeing across the first two decades of life: an analysis of 40 low-income and middle-income countries in the Asia-Pacific region.
Kennedy E, Binder G, Humphries-Waa K, Tidhar T, Cini K, Comrie-Thomson L, Vaughan C, Francis K, Scott N, Wulan N, Patton G, Azzopardi P
Lancet Glob Health. 2020 Oct; 8(12):e1473-e1488
- Estimating risks associated with early reopening in Victoria. (Policy Brief prepared for the Victorian Department of Health and Human Services)
Abeysuriya R, Delport D, Hellard M, Scott N
Know-C19 Hub. 2020 Sep
- Cost-effectiveness of uterine tamponade devices for the treatment of postpartum haemorrhage: A systematic review.
Vogel JP, Wilson AN, Scott N, Widmer M, Althabe F, Oladapo OT
Int J Gynaecol Obstet. 2020 Sep; 151(3):333-340
- Authors' response to Letter to the Editor: "Colombian experience in the management of hepatitis C".
Schroeder S, Pedrana A, Scott N, Hellard M
Liver Int. 2020 Sep; 40(12):3142-3143
- Cost-effectiveness of strategies to improve HCV screening, linkage-to-care and treatment in remand prison settings in England.
Mohamed Z, Scott N, Al-Kurdi D, Selvapatt N, Thursz MR, Lemoine M, Brown AS, Nayagam S.
Liver Int. 2020 Aug; 40(12):2950-2960
- Global hepatitis C elimination: an investment framework.
Pedrana A, Howell J, Scott N, Schroeder S, Kuschel C, Lazarus JV, Atun R, Baptista-Leite R, 't Hoen E, Hutchinson SJ, Aufegger L, Peck R, Sohn AH, Swan T, Thursz M, Lesi O, Sharma M, Thwaites J, Wilson DP, Hellard M
Lancet Gastroenterol Hepatol. 2020 Jul; 5(10):927-939
- A model of the economic benefits of global hepatitis C elimination: an investment case.
Scott N, Kuschel C, Pedrana A, Schroeder S, Howell J, Thompson A, Wilson DP, Hellard M
Lancet Gastroenterol Hepatol. 2020 Jul; 5(10):940-947
- The potential impact of a gel-based point-of-sex intervention in reducing gonorrhoea incidence among gay and bisexual men: a modelling study.
Traeger MW, Tidhar T, Holt M, Williams C, Wright EJ, Stoové MA, Scott N, Hellard ME
Sex Transm Dis. 2020 Jul; 47(10):649-657
- Use of controlled temperature chain and compact prefilled auto-disable devices to reach 2030 hepatitis B birth dose vaccination targets in LMICs: a modelling and cost-optimisation study.
Seaman CP, Morgan C, Howell J, Xiao Y, Spearman CW, Sonderup M, Lesi O, Andersson MI, Hellard ME, Scott N
Lancet Glob Health. 2020 Jul; 8(7):e931-e941
- Enhancing the hepatitis B care cascade in Australia: a cost-effectiveness model.
Xiao Y, Howell J, van Gemert C, Thompson AJ, Seaman CP, McCulloch K, Scott N, Hellard ME
J Viral Hepat. 2020 May; 27(5):526-536
- Measuring hepatitis C virus elimination as a public health threat:beyond global targets.
van Santen DK, Sacks-Davis R, Doyle JS, Scott N, Prins M, Hellard M
J Viral Hepat. 2020 Mar; 27(8):770-773
- Australia needs to increase testing to achieve hepatitis C elimination.
Scott N, Sacks-Davis R, Wade AJ, Stoové M, Pedrana A, Doyle JS, Thompson AJ, Wilson DP, Hellard ME
Med J Aust. 2020 Mar; 212(8):365-370
- Motivations for crystal methamphetamine-opioid co-injection/co-use amongst community-recruited people who inject drugs: a qualitative study.
Palmer A, Scott N, Dietze P, Higgs P
Harm Reduct J. 2020 Feb; 17(1):14
- Blood donation amongst people who inject drugs in Australia: research supporting policy change.
Quinn B, Pearson R, Cutts J, Seed C, Scott N, Hoad V, Dietze P, Wilson D, Maher L, Thompson A, Farrell M, Harrod M, Caris S, Pink J, Kotsiou G, Hellard M
Vox Sang. 2020 Feb; 115(3):162-70
- A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment.
Palmer AY, Wade AJ, Draper B, Howell J, Doyle JS, Petrie D, Thompson AJ, Wilson DP, Hellard ME, Scott N
Int J Drug Policy. 2020 Feb; 76:102633
- Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection.
Scott N, Snell G, Westall G, Pilcher D, Raggatt M, Walker RG, Hellard M, Peleg AY, Doyle J
Sci Rep. 2020 Jan; 10(1):1459
- Modelling the impact of migrants on the success of the HIV care and treatment program in Botswana.
Marukutira T, Scott N, Kelly SL, Birungi C, Makhema JM, Crowe S, Stoové M, Hellard M
PLoS One. 2020 Jan; 15(1):e0226422
- Treading lightly: Finding the best way to use public health surveillance of hepatitis C diagnoses to increase access to cure.
Stoové M, Wallace J, Higgs P, Pedrana A, Goutzamanis S, Latham N, Scott N, Treloar C, Crawford S, Doyle J, Hellard M
Int J Drug Policy. 2020 Jan; 75:102596
- Outcomes of treatment for hepatitis C in primary care compared to hospital-based care: a randomised controlled trial in people who inject drugs.
Wade AJ, Doyle JS, Gane E, Stedman C, Draper B, Iser D, Roberts SK, Kemp W, Petrie D, Scott N, Higgs P, Agius PA, Roney J, Stothers L, Thompson AJ, Hellard ME
Clin Infect Dis. 2020 Jan; 70(9):1900-1906
- Profiling Mycobacterium tuberculosis transmission and the resulting disease burden in the five highest tuberculosis burden countries.
Ragonnet R, Trauer JM, Geard N, Scott N, McBryde ES
BMC Med. 2019 Nov; 17(1):208
- The case for a universal hepatitis C vaccine to achieve hepatitis C elimination.
Scott N, Wilson DP, Thompson AJ, Barnes E, El-Sayed M, Benzaken AS, Drummer HE, Hellard ME
BMC Med. 2019 Sep; 17(1):175
- Innovative strategies for the elimination of viral hepatitis at a national level: a country case series.
Schroeder ES, Pedrana A, Scott N, Wilson D, Kuschel C, Aufegger L, Atun R, Baptista-Leite R, Butsashvili M, El-Sayed M, Getahun A, Hamid S, Hammad R, 't Hoen E, Hutchinson SJ, Lazarus JV, Lesi O, Li W, Mohamed RB, Olafsson S, Peck R, Sohn AH, Sonderup M, Spearman CW, Swan T, Thursz M, Walker T, Hellard M, Howell J
Liver Int. 2019 Aug; 39(10):1818-1836
- Additional resource needs for viral hepatitis elimination through universal health coverage: projections in 67 low-income and middle-income countries, 2016-30.
Tordrup D, Hutin Y, Stenberg K, Lauer JA, Hutton DW, Toy M, Scott N, Bulterys M, Ball A, Hirnschall G
Lancet Glob Health. 2019 Jul; 7(9):e1180-e1188
- Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.
Doyle JS, Scott N, Sacks-Davis R, Pedrana AE, Thompson AJ, Hellard ME; Eliminate Hepatitis C Partnership
Aliment Pharmacol Ther. 2019 Mar; 49(9):1223-1229
- Estimating the syphilis epidemic among gay, bisexual and other men who have sex with men in Australia following changes in HIV care and prevention.
Wilkinson A, Scott N, Tidhar T, Luong P, El-Hayek C , Wilson D, Fairley C, Zhang L, Leslie D , Roth N , Tee BK , Hellard M , Stoové M
Sex Health. 2019 Feb; 16(3):254-262
- Outcomes of treatment for hepatitis C in prisoners using a nurse-led, state-wide model of care.
Papaluca T, McDonald L, Craigie A, Gibson A, Desmond P, Wong D, Winter R, Scott N, Howell J, Doyle J, Pedrana A, Lloyd A, Stoové M, Hellard M, Iser D, Thompson A
J Hepatol. 2019 Jan; 70(5):839-846
- Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
Doan TN, Fox GJ, Meehan MT, Scott N, Ragonnet R, Viney K, Trauer JM, McBryde ES
J Antimicrob Chemother. 2019 Jan; 74(1):218-227
- Analysis of time of drug use according to needle and syringe program operating hours in Melbourne, Australia: Effects on individual-level needle and syringe coverage.
O'Keefe D, Aitken C, Scott N, Dietze P
Drug Alcohol Depend. 2018 Aug; 191:259-265
- Implications of population-level immunity for the emergence of artemisinin-resistant malaria: a mathematical model.
Scott N, Ataide R, Wilson DP, Hellard M, Price RN, Simpson JA, Fowkes FJI
Malar J. 2018 Aug; 17(1):279
- Eliminating hepatitis C: the importance of frequent testing of people who inject drugs in high prevalence settings.
Scott N, Sacks-Davis R, Pedrana A, Doyle J, Thompson A, Hellard M
J Viral Hepat. 2018 Jul; 25(12):1472-1480
- Determining the effective dose of street-level heroin: A new way to consider fluctuations in heroin purity, mass and potential contribution to overdose.
Stam NC, Gerostamoulos D, Gerstner-Stevens J, Scott N, Smith K, Drummer OH, Pilgrim JL
Forensic Sci Int. 2018 Jul; 290:219-226
- Hepatitis C virus notification rates in Australia are highest in socioeconomically disadvantaged areas.
Hainsworth SW, Dietze PM, Wilson DP, Sutton B, Hellard ME, Scott N
PLoS One. 2018 Jun; 13(6):e0198336
- Cost-effectiveness of the controlled temperature chain for the hepatitis B virus birth dose vaccine in various global settings: a modelling study.
Scott N, Palmer A, Morgan C, Lesi O, Spearman CW, Sonderup M, Hellard M
Lancet Glob Health. 2018 Jun; 6(6):e659-e667
- Eliminating HIV/HCV co-infection in gay and bisexual men: is it achievable through scaling up treatment?
Sacks-Davis R, Pedrana AE, Scott N, Doyle JS, Hellard ME
Expert Rev Anti Infect Ther. 2018 May; 16(5):411-422
- Aiming for elimination: outcomes of a consultation pathway supporting regional general practitioners to prescribe direct acting antiviral therapy for hepatitis C.
Wade AJ, McCormack A, Roder C, McDonald K, Davies M, Scott N, Wardrop M, Athan E, Hellard ME
J Viral Hepat. 2018 Apr; 25(9):1089-1098
- Heterogeneity in hepatitis C treatment prescribing and uptake in Australia: a geospatial analysis of a year of unrestricted treatment access.
Scott N, Hainsworth SW, Sacks-Davis R, Pedrana A, Doyle J, Wade A, Hellard M
J Virus Erad. 2018 Apr; 4(2):108-114
- Optima Nutrition: an allocative efficiency tool to reduce childhood stunting by better targeting of nutrition-related interventions.
Pearson R, Killedar M, Petravic J, Kakietek JJ, Scott N, Grantham KL, Stuart RM, Kedziora DJ, Kerr CC, Skordis-Worrall J, Shekhar M, Wilson DP
BMC Public Health. 2018 Mar; 18(1):384
- Achieving 90-90-90 HIV targets will not be enough to achieve the HIV incidence reduction target in Australia.
Scott N, Stoové M, Kelly SL, Wilson DP, Hellard ME
Clin Infect Dis. 2018 Mar; 66(7):1019-1023
- Achieving hepatitis C elimination in Europe - to treatment scale up and beyond.
Hellard M, Scott N, Sacks Davis R, Pedrana A
J Hepatol. 2018 Feb; 68(3):383-385
- Modelling the elimination of hepatitis C as a public health threat in Iceland: a goal attainable by 2020.
Scott N, Ólafsson S, Gottfreðsson M, Tyrfingsson T, Rúnarsdóttir V, Hansdottir I, Benitez Hernandez U, Sigmundsdóttir G, Hellard M
J Hepatol. 2018 Feb; 68(5):932-939
- Eliminating hepatitis C virus as a public health threat among HIV-positive men who have sex with men: a multi-modelling approach to understand differences in sexual risk behaviour.
Scott N, Stoové M, Wilson DP, Keiser O, El-Hayek C, Doyle J, Hellard M
J Int AIDS Soc. 2018 Jan; 21(1):e25059
- Assessing individual-level needle and syringe coverage parameters and the measurement of coverage in Melbourne, Australia: methods and impacts.
O'Keefe D, Scott N, Aitken C, Dietze P
J Public Health. 2018 Jan; 40(3):e336-e342
- Maximizing the impact of malaria funding through allocative efficiency: using the right interventions in the right locations.
Scott N, Hussain SA, Martin-Hughes R, Fowkes FJI, Kerr CC, Pearson R, Kedziora DJ, Killedar M, Stuart RM, Wilson DP
Malar J. 2017 Sep; 16(1):368
- Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade.
Scott N, Doyle JS, Wilson DP, Wade A, Howell J, Pedrana A, Thompson A, Hellard ME
Int J Drug Policy. 2017 Sep; 47:107-116
- Using simulation modelling to examine the impact of venue lockout and last-drink policies on drinking-related harms and costs to licensees.
Scott N, Livingston M, Reporter I, Dietze P
Aust N Z J Public Health. 2017 Jun; 41(3):243-247
- Longitudinal changes in personal wellbeing in a cohort of people who inject drugs.
Scott N, Carrotte ER, Higgs P, Stoové MA, Aitken CK, Dietze PM
PLoS One. 2017 May; 12(5):e0178474
- Longitudinal analysis of change in individual-level needle and syringe coverage amongst a cohort of people who inject drugs in Melbourne, Australia.
O'Keefe D, Scott N, Aitken C, Dietze P
Drug Alcohol Depend. 2017 Apr; 176:7-13
- Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model.
Scott N, McBryde ES, Thompson A, Doyle JS, Hellard ME
Gut. 2017 Mar; 66(8):1507-1515
- Targeted direct-acting antiviral treatment for chronic hepatitis C: a financial reality or an obstacle to elimination?
Hellard M, Pedrana A, Scott N
J Hepatol. 2017 Feb; 66(2):270-272
- Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001-2012: a multi-level modelling analysis.
Snow K, Scott N, Clothier HJ, MacLachlan JH, Cowie B
Aust N Z J Public Health. 2017 Feb; 41(2):193-198
- Longitudinal changes in psychological distress in a cohort of people who inject drugs in Melbourne, Australia.
Scott N, Carrotte ER, Higgs P, Cogger S, Stoové MA, Aitken CK, Dietze PM
Drug and Alcohol Dependence. 2016 Aug; 168:140-146
- Individual-level needle and syringe coverage in Melbourne, Australia: a longitudinal, descriptive analysis.
O'Keefe D, Scott N, Aitken C, Dietze P
BMC Health Serv Res. 2016 Aug; 16(1):411
- The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
Stone J, Martin NK, Hickman M, Hellard M, Scott N, McBryde E, Drummer H, Vickerman P
PLoS One. 2016 May; 11(5):e0156213
- The introduction of CCTV and associated changes
in heroin purchase and injection settings in Footscray,
Scott N, Higgs P, Caulkins JP, Aitken C, Cogger S, Dietze P
J Exp Criminol. 2016 Apr; 12(2):265-275
- How is methamphetamine typically purchased
and used in Melbourne, Australia? Reports from a
cohort of people who inject drugs.
Scott N, Caulkins JP, Dietze P
Addiction Research and Theory. 2016 Mar; 24(5):416-425
- The effects of extended public transport operating hours and venue lockout policies on drinking-related harms in Melbourne, Australia: Results from SimDrink, an agent-based simulation model.
Scott N, Hart A, Wilson J, Livingston M, Moore D, Dietze P
Int J Drug Policy. 2016 Feb; 32:44-49
- Modelling hepatitis C virus transmission among people who inject drugs: assumptions, limitations and future challenges.
Scott N, Hellard M, McBryde E
Virulence. 2016 Feb; 7(2):201-208
- Cost-effectiveness of treating chronic hepatitis C virus with direct-acting antivirals in people who inject drugs in Australia.
Scott N, Iser D, Thompson A, Doyle J, Hellard M
J Gastroenterol Hepatol. 2016 Feb; 31(4):872-882
- SimDrink: An agent-based NetLogo model of young, heavy drinkers for conducting alcohol policy experiments.
Scott N, Livingston M, Hart A, Wilson J, Moore D, Dietze P
JASS. 2016 Jan; 19(1):10
- Modelling the Impact of Condom Distribution on the Incidence and Prevalence of Sexually Transmitted Infections in an Adult Male Prison System.
Scott N, McBryde E, Kirwan A, Stoové M
PLoS One. 2015 Dec; 10(12):e0144869
- The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments.
Scott N, McBryde E, Vickerman P, Martin NK, Stone J, Drummer H, Hellard M
BMC Med. 2015 Aug; 13:198
- The changing landscape of hepatitis C treatment-not 'can we cure?' but 'who should we cure first?' Is this an ethical approach?
Hellard M, Scott N
Addiction. 2015 Jun; 110(6):984-985
- How patterns of injecting drug use evolve in a cohort of people who inject drugs.
Scott N, Caulkins JP, Ritter A, Dietze P
Trend Issues Crime Crim Justice. 2015 Jun; 502:1-20
- Understanding and describing Australian illicit drug markets: Drug price variations and associated changes in a cohort of people who inject drugs.
Scott N, Caulkins JP, Dietze P, Ritter A
National Drug Law Enforcement Research Fund. 2015 May; Monograph 58
- Patterns of drug preference and use among people who inject drugs
in Melbourne, Australia
Scott N, Caulkins JP, Ritter A, Dietze P
Addict Res Theory. 2015 Apr; 23(6):459-468
- High-Frequency Drug Purity and Price Series as Tools for Explaining Drug Trends and Harms in Victoria, Australia.
Scott N, Caulkins JP, Ritter A, Quinn C, Dietze P
Addiction. 2015 Jan; 110(1):120-128
News Articles (32)